Purchase this article with an account.
Hiroyuki Shimizu, Hiroshi Goto, Yoshihiko Usui, Naoya Nezu, Kinya Tsubota, Marina Ogawa, Masaki Asakage; Differentiation of orbital lymphoproliferative diseases by metabolomics. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3581.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Orbital lymphoproliferative diseases, particularly mucosa-associated lymphoid tissue (MALT) lymphoma and IgG4-related ocular disease (IgG4-ROD), have similar clinical and also histopathological features, and are therefore often difficult to differentiate. Metabolomics is a method of comprehensive analysis of metabolites, and has recently been applied to search for biomarkers and elucidation of pathological conditions. In this study, we analyzed and compared IgG4-ROD and MALT lymphoma by metabolomics, which has not been reported previously.
Six samples of orbital MALT lymphoma (mean age 62.3 years; 4 males and 2 females) and 11 samples of IgG 4-ROD（mean age 64.8 years, 4 males and 7 females) were analyzed. Using liquid chromatography with time-of-flight mass spectrometry (LC/TOF-MS), lipid soluble metabolites were measured. Comparison was made using orbital adipose tissue of the same case as control. To eliminate the influence of individual differences, the two diseases were compared after determining the difference between the lesion and the control in each case.
Compared with orbital adipose tissue of the same case, significant differences in expression of 174 metabolites were observed in IgG4-ROD and significant differences of 132 metabolites were found in MALT lymphoma. In the comparison between IgG4-ROD and MALT lymphoma, significant differences in expression were observed in 12 metabolites. Principal component analysis confirmed that it was possible to differentiate among four groups: adipose tissue, tumor tissue, IgG4-ROD, and MALT lymphoma
Metabolomics may be useful for the differentiation of lymphoproliferative diseases in the orbit and may lead to elucidation of the pathogenesis of these diseases.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only